Regulation of lipid metabolism in pulmonary Type 2 cells

肺2型细胞脂质代谢的调节

• 批准号: 10367413
• 负责人: Itsaso Garcia-Arcos
• 金额: $ 56.26万
• 依托单位: SUNY DOWNSTATE MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-12-20 至 2026-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10367413
• 关键词: A549; ABCA3 gene; ATP binding cassette transporter 1; Acute; Address; Adipose tissue; Adult; Agonist; Air; Alveolar; Alveolar Cell; Anti-Inflammatory Agents; Apical; Area; Bleomycin; Bronchoalveolar Lavage; Cell Culture System; Cell Differentiation process; Cell Line; Cell physiology; Cells; Cholesterol; Cholesterol Esters; Chronic Disease; Chronic Obstructive Pulmonary Disease; Chronic lung disease; Coculture Techniques; Collagen; Complex; Data; Defect; Deposition; Development; Diagnosis; Disease; Down-Regulation; Electron Microscopy; Ensure; Epithelial; Event; Fibroblasts; Fibrosis; Foundations; Gene Expression; Genetic; Genetic Models; Genetic Transcription; Hepatic; Homeostasis; Human; Hydrolysis; In Vitro; Inflammation; Inflammatory; Interleukin-1 beta; Intervention; Knock-out; Knockout Mice; Knowledge; LDL-Receptor Related Protein 1; Lecithin; Lipids; Lipoprotein (a); Lipoprotein Receptor; Lipoproteins; Liquid substance; Low Density Lipoprotein Receptor; Lung; Lung diseases; Measures; Mediating; Membrane; Mesenchymal; Metabolic; Metabolic Pathway; Metabolism; Molecular; Morphology; Mus; Outcome; PPAR alpha; PPAR gamma; Pathology; Pathway Analysis; Pathway interactions; Patients; Peptide Hydrolases; Peroxisome Proliferator-Activated Receptors; Phenotype; Phospholipids; Process; Proteins; Proteomics; Pulmonary Fibrosis; Pulmonary Pathology; Pulmonary Surfactants; Pulmonology; Regulation; Research; Respiratory physiology; Role; Science; Serpins; Signal Transduction; Smooth Muscle Myocytes; Source; Surface Tension; Surfactant therapy; Tamoxifen; Techniques; Testing; Tissues; Tracer; Vital capacity; Work of Breathing; adipocyte differentiation; alveolar epithelium; alveolar lamellar body; cytokine; extracellular; idiopathic pulmonary fibrosis; in vivo; in vivo Model; innovation; intercellular communication; knock-down; lipid biosynthesis; lipid mediator; lipid metabolism; lipidomics; mRNA Expression; macrophage; novel; novel therapeutic intervention; novel therapeutics; prevent; pulmonary arterial hypertension; pulmonary function; receptor; response; restoration; single-cell RNA sequencing; small hairpin RNA; surfactant; surfactant deficiency; surfactant production; surfactant replacement therapy; synthetic enzyme; therapeutic target; transcriptome sequencing; transcriptomics; uptake

Surfactant insufficiency compromises pulmonary compliance and respiratory function in multiple pulmonary pathologies. Our understanding of surfactant metabolism in adult pulmonary disease is very limited and this restricts the potential for therapeutic targeting. In this project, we have generated a new genetic model of surfactant insufficiency in adult disease by deleting the low-density lipoprotein receptor related protein 1 (LRP1) specifically in surfactant producing type 2 cells (AEC2). LRP1 functions as lipoprotein receptor and extracellular protease clearing receptor and it is associated with decreased respiratory function in patients with COPD and pulmonary arterial hypertension. Studies in our generated cell line of LRP1 knockdown AEC2 (LRP1 KD) and tamoxifen-inducible AEC2-specific LRP1 knockout mice (SPC-LRP1-/-) show that LRP1 is required to maintain surfactant lipid secretion and intracellular lipid homeostasis to ensure optimal pulmonary compliance and respiratory function. We hypothesize that LRP1 controls surfactant metabolism in AEC2 and we will study the regulatory mechanisms. In Aim 1 we will decipher the mechanism of action of LRP1 at the membrane level in AEC2 and its regulation of the lipid source for surfactant synthesis in AEC2. In Aim 2 we will investigate the epithelial to mesenchymal cross talk and the role of LRP1 in the progressive decline in lung function during profibrotic challenges and molecular mechanisms responsible. We will attempt a new therapeutic approach to stop the decline. This proposal is innovative conceptually and technically. The role of AEC2 lipid metabolism during adult pulmonary disease is unknown. LRP1 regulates many cellular functions through lipid metabolism in different tissues and our study shows that it also regulates pulmonary function through surfactant lipid metabolism. In addition, we use novel techniques that include inducible and cell-specific genetic knockout models in vivo lipid tracing and -omics analysis. Surfactant homeostasis enables basic pulmonary function, but the regulation of surfactant homeostasis in adult disease is very little understood. The significance of this research is further underscored by the fact that surfactant lipid is altered in multiple pulmonary pathologies, including the most prevalent ones.

表面活性剂功能不全损害多种肺部的肺合顺顺和呼吸功能 病理。我们对成年肺疾病中表面活性剂代谢的理解非常有限，这 限制了治疗靶向的潜力。在这个项目中，我们生成了一个新的遗传模型 通过删除低密度脂蛋白受体相关蛋白1（LRP1），表面活性剂不足 特别是在产生2型细胞的表面活性剂中（AEC2）。 LRP1充当脂蛋白受体和细胞外 蛋白酶清除受体，并且与COPD患者的呼吸功能降低有关 肺动脉高压。在我们生成的LRP1敲低AEC2（LRP1 KD）的细胞系中的研究和 他莫昔芬 - 可诱导的AEC2特异性LRP1敲除小鼠（SPC-LRP1 - / - ）表明LRP1需要维持 表面活性剂脂质分泌和细胞内脂质稳态，以确保最佳肺合顺顺和 呼吸功能。我们假设LRP1控制AEC2中的表面活性剂代谢，我们将研究 监管机制。在AIM 1中，我们将在膜一级的LRP1的作用机理 AEC2及其调节AEC2中表面活性剂合成的脂质源。在AIM 2中，我们将调查 上皮到间充质交叉谈话和LRP1在肺功能逐渐下降中的作用 负责的纤维化挑战和分子机制。我们将尝试一种新的治疗方法 停止下降。 该建议在概念和技术上都是创新的。 AEC2脂质代谢在成人中的作用 肺部疾病尚不清楚。 LRP1通过不同的脂质代谢调节许多细胞功能 组织和我们的研究表明，它还通过表面活性剂脂质代谢来调节肺功能。在 此外，我们使用的新技术包括体内脂质中的诱导和细胞特异性遗传敲除模型 跟踪和 - 组分析。表面活性剂稳态可以实现基本的肺功能，但调节 表面活性剂稳态在成人疾病中鲜为人知。这项研究的意义进一步 在多种肺部病理中改变了表面活性剂脂质的事实，包括最多 普遍。